Betta Pharmaceuticals Co., Ltd.

Other

Fujian Haixi Pharmaceuticals, Inc.

Betta Pharmacueticals Co., Ltd.

Kang, Xinshan

Xiaoyan Shen

Wei Long

Yinxiang Wang

Fenlai Tan

Yanping Wang

Yunyan Hu

Shaojing Hu

Cunbo Ma

Fei Wang

Lieming Ding

Hong Cao

Xinshan Kang

Xiangdong Zhao

The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders. 

Compound for increasing kinase active and application thereof

This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder 

Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar. 

Glucagon-like peptide-1 analogues and uses thereof

Growing community of inventors

Beijing, China

Xiaoyan Shen